Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ifosfamide in pediatric malignant solid tumors.

C B Pratt1, E C Douglass, E L Etcubanas

  • 1Division of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101.

Cancer Chemotherapy and Pharmacology
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electron correlation effects on the femtosecond dephasing dynamics of E22 excitons in (6,5) carbon nanotubes.

The journal of physical chemistry. A·2011
Same author

Successful treatment of metastatic choriocarcinoma after DMP 840.

Urologic oncology·2011
Same author

Exciton dynamics in semiconducting carbon nanotubes.

The journal of physical chemistry. B·2010
Same author

Crystal line aldolase and its identity with myogen A.

Federation proceedings·2010
Same author

The vascular action of beta-dimethylaminoethyl benzhydryl etherhydrochloride (benadryl).

Federation proceedings·2010
Same author

Phonon-assisted electroluminescence from metallic carbon nanotubes and graphene.

Nano letters·2010

Ifosfamide/mesna chemotherapy showed efficacy in pediatric malignant solid tumors, including sarcomas and neuroblastoma. While generally well-tolerated, potential toxicities like myelosuppression and neurotoxicity require careful monitoring.

Area of Science:

  • Pediatric Oncology
  • Medical Chemotherapy
  • Clinical Pharmacology

Background:

  • Malignant solid tumors in children pose significant treatment challenges.
  • Ifosfamide is a potent alkylating agent with demonstrated activity against various pediatric cancers.
  • Mesna is used to mitigate ifosfamide-induced urotoxicity.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of ifosfamide/mesna in pediatric patients with malignant solid tumors.
  • To identify tumor types that respond to this chemotherapy regimen.
  • To characterize the safety profile of ifosfamide/mesna in this population.

Main Methods:

  • A cohort of 97 pediatric patients with malignant solid tumors received ifosfamide (1.6 g/m2 daily x 5) and mesna (400 mg/m2 at specified intervals).

Related Experiment Videos

  • Intravenous administration of both agents was employed.
  • Tumor response and adverse events were systematically recorded.

    • Main Results:

    • Positive responses were observed across a spectrum of pediatric malignancies, including osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, neuroblastoma, and germ-cell tumors.
    • Common toxicities included nausea, vomiting, myelosuppression, and transient elevations in BUN, creatinine, and liver enzymes.
    • Self-limiting neurotoxicity was noted, particularly in patients with prior cisplatin exposure.

    Conclusions:

    • Ifosfamide/mesna demonstrates significant activity in treating diverse malignant solid tumors in pediatric patients.
    • The regimen is associated with manageable toxicities, though neurotoxicity warrants attention, especially in pre-treated patients.
    • Further investigation in combination therapies and alternative dosing schedules is recommended for ifosfamide in pediatric oncology.